| Message: | In November 2018, the U.S. Food and FDA has accepted Gattex（main ingredients is Teduglutide）supplement application (sNDA). The sNDA has applied for approval to expand the indications of Gattex injection for the treatment of pediatric patients (1-17 years old) with short bowel syndrome (SBS) dependent on parenteral support.
Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue. In clinical studies, Teduglutide increased the growth, proliferation and repair of cells in the lining of the small intestine, and the increased number of cells was beneficial to intestinal absorption and reduced diarrhea.It also reduces gastric emptying and secretion. url:http://www.gtpeptide.com |
my account